等离子膀胱肿瘤电切术后吉西他滨膀胱灌注化疗在浅表性膀胱癌患者中的应用效果  

Effect of gemcitabine intravesical infusion chemotherapy in patients with superficial bladder cancer after plasmakinetic resection of bladder tumor

作　　者：方亮 汪婷 汪建焜 FANG Liang;WANG Ting;WANG Jiankun(Department of Urology,the First People’s Hospital of Jingdezhen,Jingdezhen 333000,Jiangxi,China)

机构地区：[1]景德镇市第一人民医院泌尿外科,江西景德镇3330000

出　　处：《癌症进展》2024年第24期2734-2736,2740,共4页Oncology Progress

摘　　要：目的探讨等离子膀胱肿瘤电切术(PKRBT)后吉西他滨膀胱灌注化疗在浅表性膀胱癌(SBC)患者中的应用效果。方法根据治疗方式的不同将60例SBC患者分为对照组(n=29)和观察组(n=31),两组患者均接受PKRBT手术,对照组患者术后接受表柔比星膀胱灌注化疗,观察组患者术后接受吉西他滨膀胱灌注化疗。比较两组患者的临床疗效、肿瘤标志物[膀胱肿瘤抗原(BTA)、癌胚抗原(CEA)、核基质蛋白22(NMP22)、糖类抗原125(CA125)]水平、不良反应发生情况及复发情况。结果观察组患者的治疗总有效率为93.55%,与对照组患者的86.21%比较,差异无统计学意义(P﹥0.05)。治疗后,两组患者血清BTA、CEA、NMP22、CA125水平均低于本组治疗前,观察组患者血清BTA、CEA、NMP22、CA125水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者的不良反应总发生率为12.90%,低于对照组患者的44.83%,复发率为0%,低于对照组患者的17.24%,差异均有统计学意义(P﹤0.05)。结论SBC患者PKRBT术后给予吉西他滨膀胱灌注化疗的治疗效果满意,可降低肿瘤标志物水平,减少复发风险,且安全性较高。Objective To investigate the effect of gemcitabine intravesical infusion chemotherapy in patients with su-perficial bladder cancer(SBC)after plasmakinetic resection of bladder tumor(PKRBT).Method According to different treatment methods,60 SBC patients were divided into control group(n=29)and observation group(n=31).All SBC pa-tients underwent PKRBT surgery,the control group received epirubicin intravesical infusion chemotherapy after surgery,while the observation group received gemcitabine intravesical infusion chemotherapy after surgery.The clinical efficacy,tumor marker[bladder tumor antigen(BTA),carcinoembryonic antigen(CEA),nuclear matrix protein 22(NMP22),car-bohydrate antigen 125(CA125)]levels,incidence of adverse reactions and recurrence were compared between the two groups.Result The total effective rate in observation group was 93.55%,which was not significantly different from 86.21%in control group(P>0.05).After treatment,the serum levels of BTA,CEA,NMP22,and CA125 in both groups were lower than those before treatment,the serum levels of BTA,CEA,NMP22,and CA125 in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).The total incidence of ad-verse reactions in observation group was 12.90%,which was lower than 44.83%in control group,the recurrence rate was 0%,which was lower than 17.24%in control group,and the differences were statistically significant(P<0.05).Conclu-sion Gemcitabine intravesical infusion chemotherapy in SBC patients after PKRBT is satisfactory,which can reduce tu-mor marker levels,decrease the risk of recurrence,and has high safety.

关 键 词：浅表性膀胱癌 吉西他滨 膀胱灌注化疗 等离子膀胱肿瘤电切术 

分 类 号：R737.14[医药卫生—肿瘤]